- Home
- GLV vs UNCY Comparison
GLV vs UNCY Comparison
Compare GLV & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLV
- UNCY
- Stock Information
- Founded
- GLV 2004
- UNCY 2016
- Country
- GLV United States
- UNCY United States
- Employees
- GLV N/A
- UNCY N/A
- Industry
- GLV Finance/Investors Services
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- GLV Finance
- UNCY Health Care
- Exchange
- GLV Nasdaq
- UNCY Nasdaq
- Market Cap
- GLV 72.1M
- UNCY 74.2M
- IPO Year
- GLV N/A
- UNCY 2021
- Fundamental
- Price
- GLV $5.82
- UNCY $4.37
- Analyst Decision
- GLV
- UNCY Strong Buy
- Analyst Count
- GLV 0
- UNCY 4
- Target Price
- GLV N/A
- UNCY $63.75
- AVG Volume (30 Days)
- GLV 54.2K
- UNCY 481.2K
- Earning Date
- GLV 01-01-0001
- UNCY 08-14-2025
- Dividend Yield
- GLV 12.44%
- UNCY N/A
- EPS Growth
- GLV N/A
- UNCY N/A
- EPS
- GLV N/A
- UNCY N/A
- Revenue
- GLV N/A
- UNCY N/A
- Revenue This Year
- GLV N/A
- UNCY N/A
- Revenue Next Year
- GLV N/A
- UNCY $3,131.28
- P/E Ratio
- GLV N/A
- UNCY N/A
- Revenue Growth
- GLV N/A
- UNCY N/A
- 52 Week Low
- GLV $4.70
- UNCY $3.40
- 52 Week High
- GLV $6.06
- UNCY $11.00
- Technical
- Relative Strength Index (RSI)
- GLV 62.14
- UNCY 49.75
- Support Level
- GLV $5.72
- UNCY $4.15
- Resistance Level
- GLV $5.85
- UNCY $4.35
- Average True Range (ATR)
- GLV 0.06
- UNCY 0.18
- MACD
- GLV 0.01
- UNCY 0.05
- Stochastic Oscillator
- GLV 88.26
- UNCY 92.16
About GLV Clough Global Dividend and Income Fund of beneficial interest
Clough Global Dividend and Income Fund is a closed-ended investment management company. The fund's investment objective is to provide a high level of total return. It invests in equity and debt securities in both U.S. and non-U.S. markets of companies of any market capitalization.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.